risperidone has been researched along with Abnormal Movements in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with choreoathetoid cerebral palsy were enrolled after parental consent and given risperidone for six-month period along with standard care." | 7.88 | Effect of Risperidone on the Motor and Functional Disability in Children With Choreoathetoid Cerebral Palsy. ( Kamate, M; Metgud, D; Mittal, N, 2018) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 5.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| "Children with choreoathetoid cerebral palsy were enrolled after parental consent and given risperidone for six-month period along with standard care." | 3.88 | Effect of Risperidone on the Motor and Functional Disability in Children With Choreoathetoid Cerebral Palsy. ( Kamate, M; Metgud, D; Mittal, N, 2018) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 1.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamate, M | 1 |
| Mittal, N | 1 |
| Metgud, D | 1 |
| Vale, TC | 1 |
| Freitas, Dda S | 1 |
| Maciel, RO | 1 |
| Miranda, EC | 1 |
| Cardoso, F | 1 |
| Caligiuri, MP | 1 |
| Teulings, HL | 1 |
| Dean, CE | 1 |
| Niculescu, AB | 1 |
| Lohr, J | 1 |
| Daoud, A | 1 |
| Chand, P | 1 |
| Cruz-Flores, S | 1 |
| Lin, YC | 2 |
| Gupta, S | 1 |
| Hoy, JS | 1 |
| Alexander, B | 1 |
1 review available for risperidone and Abnormal Movements
| Article | Year |
|---|---|
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
6 other studies available for risperidone and Abnormal Movements
| Article | Year |
|---|---|
Effect of Risperidone on the Motor and Functional Disability in Children With Choreoathetoid Cerebral Palsy.
Topics: Anti-Dyskinesia Agents; Cerebral Palsy; Child; Child, Preschool; Chorea; Dyskinesias; Female; Humans | 2018 |
Teaching Video NeuroImages: hemichorea-hemiballismus secondary to nonketotic hyperglycemia.
Topics: Antipsychotic Agents; Brain; Chorea; Diabetes Mellitus, Type 2; Dyskinesias; Female; Humans; Hypergl | 2013 |
Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Topics: Adult; Age of Onset; Antipsychotic Agents; Confidence Intervals; Depression; Drug Monitoring; Dyskin | 2009 |
Segmental ballism due to acute ischemic lesions of the caudate nucleus and parietal lobe: case report and review of the literature.
Topics: Aged, 80 and over; Antipsychotic Agents; Brain Ischemia; Caudate Nucleus; Cerebral Infarction; Cereb | 2011 |
Prolonged hemiballism after the remission of non-ketotic hyperosmolar syndrome.
Topics: Aged; Blood Glucose; Brain; Dopamine Antagonists; Dyskinesias; Female; Humans; Ketone Bodies; Magnet | 2012 |
Rabbit syndrome secondary to risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Depressive Disorder, M | 2002 |